Safety Profile of Bremelanotide Across the Clinical Development Program.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Safety Profile of Bremelanotide Across the Clinical Development Program.
- Published In:
- Journal of women's health (2002), 31(2), 171-182 (2022)
- Authors:
- Clayton, Anita H, Kingsberg, Sheryl A, Portman, David, Sadiq, Amama, Krop, Julie, Jordan, Robert, Lucas, Johna, Simon, James A
- Database ID:
- RPEP-06057
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06057APA
Clayton, Anita H; Kingsberg, Sheryl A; Portman, David; Sadiq, Amama; Krop, Julie; Jordan, Robert; Lucas, Johna; Simon, James A. (2022). Safety Profile of Bremelanotide Across the Clinical Development Program.. Journal of women's health (2002), 31(2), 171-182. https://doi.org/10.1089/jwh.2021.0191
MLA
Clayton, Anita H, et al. "Safety Profile of Bremelanotide Across the Clinical Development Program.." Journal of women's health (2002), 2022. https://doi.org/10.1089/jwh.2021.0191
RethinkPeptides
RethinkPeptides Research Database. "Safety Profile of Bremelanotide Across the Clinical Developm..." RPEP-06057. Retrieved from https://rethinkpeptides.com/research/clayton-2022-safety-profile-of-bremelanotide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.